• Mechanism of Action
• A monoclonal antibody directed against the HER2 receptor, which is involved in cell signalling and is overexpressed in certain cancers. Inhibition of HER2 signalling pathways results in cell cycle arrest; the monoclonal antibody also mediates antibody-dependent cell-mediated cytotoxicity.

Clinical Use

• • Indications
• • Contraindications
  • Left ventricular dysfunction, as evidenced by an LVEF <45%, or symptomatic heart failure.
• • Adverse Effects